Autoimmune Diseases Clinical Trial
Official title:
Characterization of the Phenotypic Markers of B Cell Lymphocytes in Rheumatoid Arthritis
Rheumatoid Arthritis (RA):
RA is a chronic inflammatory autoimmune disease that primarily affects the small joints,
eventually leading to bone erosion and an inability to move (1). Several immune cells
participate in the pathogenesis of RA. One of those cells is B cell.
B cell population:
B lymphocytes play several critical roles in the pathogenesis of rheumatoid arthritis. They
are the source of the rheumatoid factors (RF) and anti-cyclic-citrullinated peptide
(anti-CCP), which contribute to immune complex formation and complement activation in the
joints (2).
There is different B cell subpopulation according to the stage of maturation and activity.
Distinction of this subpopulation can be done by detection of different CD molecules
expressed on cell surface (3). From all sub-population this research will focus on these
immunophenotypes; immature, mature, memory and B-reg cells by using CD 19, CD24, CD38 & CD27
respectively.
Joa˜ o E. Fonseca and his team found the reduction in B cell subpopulation especially (Pre-
switched memory B cells) both in RA and Arthritis in the early stage. This observation not
related to using methotrexate or corticosteroid in the treatment. They used the
classification of B cells with CD 19 mainly and then IgD and CD27 to identify B cells (4).
Gabriella Sármay team found that the number of B-reg CD19+ CD27+ IL-10+ cells in peripheral
blood is fewer in RA patients compared with healthy controls (5).
Interleukin 10:
Interleukin (IL)-10 functions as an anti-inflammatory cytokine in rheumatoid arthritis. IL-10
mRNA levels were significantly elevated in synovial fluid mononuclear cells (SFMCs) from
patients with RA compared with PBMCs peripheral blood mononuclear cells (PBMCs) from RA
patients or healthy volunteers according to Isomäki P (6).
IL 10 is primarily produced by monocytes mainly and, then by lymphocytes; type 2 T helper
cells (TH2), mast cells, CD4+CD25+Foxp3+ regulatory T cells, and in a certain subset of
activated T cells and B cells (7).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04078698 -
Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
| Recruiting |
NCT05670301 -
Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases
|
N/A | |
| Completed |
NCT03266172 -
A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses
|
Phase 1 | |
| Completed |
NCT03649412 -
A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772
|
Phase 1 | |
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
| Completed |
NCT00975936 -
Phase 0 Microdose Study
|
Phase 1 | |
| Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
| Completed |
NCT01210716 -
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
|
Phase 3 | |
| Completed |
NCT00820469 -
Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
|
Phase 4 | |
| Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
| Withdrawn |
NCT03239600 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)
|
Phase 2 | |
| Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
| Recruiting |
NCT06019611 -
Epidural Stimulation in Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT05030779 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
|
Early Phase 1 | |
| Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
| Completed |
NCT04005456 -
Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design
|
N/A | |
| Recruiting |
NCT05085444 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
|
Early Phase 1 | |
| Recruiting |
NCT05853835 -
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
|
Phase 1 |